Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor β-gene

被引：0
|
作者：
Bastie, JN
Garcia, I
Terré, C
Cross, NCP
Mahon, FX
Castaigne, S
机构：
[1] Salisbury Dist Hosp, Dept Hematol & Oncol, Salisbury, Wilts, England
[2] Salisbury Dist Hosp, Dept Biochem Haematol & Cytogenet, Salisbury, Wilts, England
[3] Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury, Wilts, England
[4] Univ Bordeaux 2, CNRS, Unite 2617, F-33076 Bordeaux, France
来源：
HAEMATOLOGICA | 2004年 / 89卷 / 10期
关键词：
atypical chronic myeloproliferative disorder; PDGFRB; t(5; 10); imatinib mesylate;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor (3 gene (PDGFRB). We used imatinib to treat a 49-year old man with atypical CMD in accelerated phase and the H4 (D10S170)-PDGFRB fusion gene. After 3 months of treatment, we observed grade 4 hematologic toxicity and a lack of response.
引用
收藏
页码：1263 / 1264
页数：2
相关论文
共 50 条
  • [21] Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer - In reply
    Mathew, P
    Fidler, IJ
    Bucana, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1333 - 1334
  • [22] Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene
    Walz, Christoph
    Metzgeroth, Georgia
    Haferlach, Claudia
    Schmitt-Graeff, Annette
    Fabarius, Alice
    Hagen, Volker
    Pruemmer, Otto
    Rauh, Stefan
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Cross, Nicholas C. P.
    Reiter, Andreas
    HAEMATOLOGICA, 2007, 92 (02) : 163 - 169
  • [23] Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and akt inactivation
    Matei, D
    Chang, DD
    Jeng, MH
    CLINICAL CANCER RESEARCH, 2004, 10 (02) : 681 - 690
  • [24] HUMAN SCHWANNOMAS EXPRESS ACTIVATED PLATELET-DERIVED GROWTH FACTOR RECEPTORS AND CKIT AND ARE GROWTH INHIBITED BY GLEEVEC (IMATINIB MESYLATE)
    Mukherjee, Joydeep
    Kamnasaran, Deepak
    Balasubramaniam, Anandh
    Radovanovic, Ivan
    Zadeh, Gelareh
    Kiehl, Tim-Rasmus
    Guha, Abhijit
    NEURO-ONCOLOGY, 2009, 11 (05) : 598 - 598
  • [25] Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex
    Shim, Ann Hye-Ryong
    Liu, Heli
    Focia, Pamela J.
    Chen, Xiaoyan
    Lin, P. Charles
    He, Xiaolin
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (25) : 11307 - 11312
  • [26] Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor:: a new clinical target for STI571/Glivec
    Trempat, P
    Villalva, C
    Laurent, G
    Armstrong, F
    Delsol, G
    Dastugue, N
    Brousset, P
    ONCOGENE, 2003, 22 (36) : 5702 - 5706
  • [27] Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate
    Swick, Brian L.
    Ravdel, Larisa
    Fitzpatrick, James E.
    Robinson, William A.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2008, 35 (02) : 197 - 202
  • [28] A Phase 2 Trial of Imatinib Mesylate in Patients With Recurrent Nonresectable Chondrosarcomas Expressing Platelet-Derived Growth Factor Receptor-α or -β An Italian Sarcoma Group Study
    Grignani, Giovanni
    Palmerini, Emanuela
    Stacchiotti, Silvia
    Boglione, Antonella
    Ferraresi, Virginia
    Frustaci, Sergio
    Comandone, Alessandro
    Casali, Paolo G.
    Ferrari, Stefano
    Aglietta, Massimo
    CANCER, 2011, 117 (04) : 826 - 831
  • [29] Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor: a new clinical target for STI571/Glivec
    Pascal Trempat
    Claire Villalva
    Guy Laurent
    Florence Armstrong
    Georges Delsol
    Nicole Dastugue
    Pierre Brousset
    Oncogene, 2003, 22 : 5702 - 5706
  • [30] Inhibition of platelet-derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro
    Fierro, F.
    Illmer, T.
    Jing, D.
    Schleyer, E.
    Ehninger, G.
    Boxberger, S.
    Bornhaeuser, M.
    CELL PROLIFERATION, 2007, 40 (03) : 355 - 366
12345